Last reviewed · How we verify
Intravenous immunoglobulin
Intravenous immunoglobulin is a Biologic drug developed by University of Calgary. It is currently FDA-approved. Also known as: Subcutaneous immunoglobulin, Gamunex, IVIG, Immunoglobulin.
At a glance
| Generic name | Intravenous immunoglobulin |
|---|---|
| Also known as | Subcutaneous immunoglobulin, Gamunex, IVIG, Immunoglobulin, IVIg |
| Sponsor | University of Calgary |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC (PHASE2)
- A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies (PHASE2)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (PHASE2, PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) (PHASE1)
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors (PHASE1, PHASE2)
- Bevacizumab In Hereditary Hemorrhagic Telangiectasia (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravenous immunoglobulin CI brief — competitive landscape report
- Intravenous immunoglobulin updates RSS · CI watch RSS
- University of Calgary portfolio CI
Frequently asked questions about Intravenous immunoglobulin
What is Intravenous immunoglobulin?
Intravenous immunoglobulin is a Biologic drug developed by University of Calgary.
Who makes Intravenous immunoglobulin?
Intravenous immunoglobulin is developed and marketed by University of Calgary (see full University of Calgary pipeline at /company/university-of-calgary).
Is Intravenous immunoglobulin also known as anything else?
Intravenous immunoglobulin is also known as Subcutaneous immunoglobulin, Gamunex, IVIG, Immunoglobulin, IVIg.
What development phase is Intravenous immunoglobulin in?
Intravenous immunoglobulin is FDA-approved (marketed).
Related
- Manufacturer: University of Calgary — full pipeline
- Also known as: Subcutaneous immunoglobulin, Gamunex, IVIG, Immunoglobulin, IVIg
- Compare: Intravenous immunoglobulin vs similar drugs
- Pricing: Intravenous immunoglobulin cost, discount & access